Medicated eye drops taken nightly for two years delays nearsightedness in children, a new study suggests.
PixelsEffect/iStock/Getty Images Plus
An eye drop a day could keep myopia at bay — at least temporarily.
Using nightly eye drops with 0.05 percent atropine, a medication that relaxes the eye muscle responsible for focusing vision, may delay myopia onset in children , researchers report February 14 in JAMA .
Myopia, also called nearsightedness, is an irreversible condition in which the eyeball grows too long front to back, causing blurred distant vision. It typically begins in childhood, and the earlier it starts, the worse eye health can become later in life. Elongated eyes increase the risk for ocular complications including cataracts, glaucoma and macular degeneration.
Headlines and summaries of the latest Science News articles, delivered to your email inbox every Thursday.
Thank you for signing up!
There was a problem signing you up.
The prevalence of myopia has risen rapidly over the last few decades. About one-fourth of the global population currently has the condition. It is expected to affect half of people worldwide by 2050.
Genetics plays a large role in the condition. A 2020 study found that myopia risk is more than 10 times as high in children of two highly myopic parents as in children of nonmyopic parents , says ophthalmologist Jason Yam of the Chinese University of Hong Kong.
But he and other scientists speculate that environmental factors such as less time outdoors and more intensive education are causing the recent boom ( SN: 1/24/13 ). “It’s happening too quickly to be a purely genetic or inherited issue,” says optometrist Kathryn Saunders of Ulster University in Coleraine, Northern Ireland, who was not involved in the new study.
Low-dose atropine eye drops are already used to slow myopia progression in several countries in Asia. Yam and colleagues wanted to see if the medication could also delay myopia onset.
The team recruited nonmyopic children ages 4 through 9 who lived in Hong Kong. Each participant received nightly eye drops but was randomly assigned to receive drops with 0.05 percent atropine, 0.01 percent atropine or a placebo. Families and clinicians didn’t know which treatment group the children were in.
A total of 353 children used their assigned eye drops for two years. Only about 25 percent of children who took 0.05 percent atropine eye drops, roughly 30 kids, developed myopia in at least one eye, compared with about 50 percent of those who used 0.01 percent atropine or placebo eye drops, around 60 kids in each group. The percentages in each group were similar for eye elongation not severe enough to be considered myopia.
Get great science journalism, from the most trusted source, delivered to your doorstep.
“It’s a great first step to encourage us to explore more,” Saunders says.
Scientists will need to conduct studies in more diverse populations and environments to reach generalizable conclusions since the trial took place in only Hong Kong. Eye color may also influence dosing, as lighter-pigmented eyes might be more susceptible to side effects, including sensitivity to light.
How atropine slows myopia onset and progression remains a mystery. The medication might improve blood circulation in the eye, Yam says, but that’s just one existing hypothesis.
The new study was too short to suggest that atropine eye drops can prevent myopia. But an ongoing follow-up period in which participants continue taking the medication through their teenage years — when eye length stabilizes — will help the team understand if atropine eye drops can ward off the condition altogether.
J.C. Yam et al . Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: The LAMP2 randomized clinical trial . Journal of the American Medical Association . Vol. 329, February 14, 2023, p. 472. doi:10.1001/jama.2022.24162.
S.M. Tang et al . Independent influence of parental myopia on childhood myopia in a dose-related manner in 2,055 trios: The Hong Kong Children Eye Study . American Journal of Ophthalmology . Vol. 218, May 22, 2020, p. 199. doi: 10.1016/j.ajo.2020.05.026.
McKenzie Prillaman is the Spring 2023 science writing intern at Science News . She holds a bachelor’s degree in neuroscience with a minor in bioethics from the University of Virginia and a master’s degree in science communication from the University of California, Santa Cruz.
Our mission is to provide accurate, engaging news of science to the public. That mission has never been more important than it is today.
As a nonprofit news organization, we cannot do it without you.
Your support enables us to keep our content free and accessible to the next generation of scientists and engineers. Invest in quality science journalism by donating today.
Science News was founded in 1921 as an independent, nonprofit source of accurate information on the latest news of science, medicine and technology. Today, our mission remains the same: to empower people to evaluate the news and the world around them. It is published by the Society for Science, a nonprofit 501(c)(3) membership organization dedicated to public engagement in scientific research and education (EIN 53-0196483).
© Society for Science & the Public 2000–2023. All rights reserved.
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.
Not a subscriber?
Become one now .
